Tumor Macrophages: Protective and Pathogenic Roles in Cancer Development

Current Topics in Developmental Biology

Volumn 94, Issue C, 2011, Pages 309-328

  Qualls, Joseph E ^a   Murray, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cancer; Inflammation; Macrophage; Solid tumor

Indexed keywords

TUMOR MARKER;

ANIMAL; BOOK; CELL DIFFERENTIATION; CELL TRANSFORMATION; CYTOLOGY; HUMAN; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; PATHOLOGY; PROGNOSIS;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; MACROPHAGES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551485129     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380916-2.00010-3     Document Type: Book

References (93)

1. Aggarwal B.B., Gehlot P. Inflammation and cancer: How friendly is the relationship for cancer patients?. Curr. Opin. Pharmacol. 2009, 9:351-369.
2. Aharinejad S., Sioud M., Lucas T., Abraham D. Target validation using RNA interference in solid tumors. Methods Mol. Biol. 2007, 361:227-238.
3. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
4. Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Harrington A.M., Shields P.G., Felley-Bosco E., Hussain S.P., Harris C.C. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl. Cancer Inst. 1999, 91:86-88.
5. Austyn J.M., Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur. J. Immunol. 1981, 11:805-815.
6. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 2002, 13:135-141.
7. Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow?. Lancet 2001, 357:539-545.
8. Baron J.A., Sandler R.S. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med. 2000, 51:511-523.
9. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., Bottazzi B., Doni A., Vincenzo B., Pasqualini F., Vago L., Nebuloni M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
10. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., Matthews V., Schmid R.M., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
11. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
12. Burdelya L., Kujawski M., Niu G., Zhong B., Wang T., Zhang S., Kortylewski M., Shain K., Kay H., Djeu J., Dalton W., Pardoll D., et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 2005, 174:3925-3931.
13. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
14. Coffelt S.B., Hughes R., Lewis C.E. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta 2009, 1796:11-18.
15. Cole S.W. Chronic inflammation and breast cancer recurrence. J. Clin. Oncol. 2009, 27:3418-3419.
16. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. 1893, 105:487-551.
17. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
18. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
19. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
20. Curran M.A., Allison J.P. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 2009, 69:7747-7755.
21. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 2010, 107(9):4275-4280.
22. Delano M.J., Scumpia P.O., Weinstein J.S., Coco D., Nagaraj S., Kelly-Scumpia K.M., O'Malley K.A., Wynn J.L., Antonenko S., Al-Quran S.Z., Swan R., Chung C.S., et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 2007, 204:1463-1474.
23. Feldmann M., Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 2003, 9:1245-1250.
24. Funada Y., Noguchi T., Kikuchi R., Takeno S., Uchida Y., Gabbert H.E. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep. 2003, 10:309-313.
25. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
26. Garcia Rodriguez L.A., Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001, 12:570-576.
27. Geissmann F., Manz M.G., Jung S., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327:656-661.
28. Glocker E.O., Kotlarz D., Boztug K., Gertz E.M., Schaffer A.A., Noyan F., Perro M., Diestelhorst J., Allroth A., Murugan D., Hatscher N., Pfeifer D., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 2009, 361:2033-2045.
29. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
30. Gorelik E., Wiltrout R.H., Brunda M.J., Holden H.T., Herberman R.B. Augmentation of metastasis formation by thioglycollate-elicited macrophages. Int. J. Cancer 1982, 29:575-581.
31. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
32. Hagemann T., Robinson S.C., Schulz M., Trumper L., Balkwill F.R., Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25:1543-1549.
33. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., Robinson S.C., Balkwill F.R. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008, 205:1261-1268.
34. Hagemann T., Biswas S.K., Lawrence T., Sica A., Lewis C.E. Regulation of macrophage function in tumors: The multifaceted role of NF-kappaB. Blood 2009, 113:3139-3146.
35. Haile L.A., von Wasielewski R., Gamrekelashvili J., Kruger C., Bachmann O., Westendorf A.M., Buer J., Liblau R., Manns M.P., Korangy F., Greten T.F. Myeloid-derived suppressor cells in inflammatory bowel disease: A new immunoregulatory pathway. Gastroenterology 2008, 135:871-881. 881 e1-5.
36. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
37. Hume D.A. Macrophages as APC and the dendritic cell myth. J. Immunol. 2008, 181:5829-5835.
38. Hume D.A., Robinson A.P., MacPherson G.G., Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoietic organs. J. Exp. Med. 1983, 158:1522-1536.
39. Hussain S.P., Amstad P., Raja K., Ambs S., Nagashima M., Bennett W.P., Shields P.G., Ham A.J., Swenberg J.A., Marrogi A.J., Harris C.C. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Res. 2000, 60:3333-3337.
40. Inghirami G., Chiarle R., Simmons W.J., Piva R., Schlessinger K., Levy D.E. New and old functions of STAT3: A pivotal target for individualized treatment of cancer. Cell Cycle 2005, 4:1131-1133.
41. Kimura Y.N., Watari K., Fotovati A., Hosoi F., Yasumoto K., Izumi H., Kohno K., Umezawa K., Iguchi H., Shirouzu K., Takamori S., Kuwano M., et al. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci. 2007, 98:2009-2018.
42. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., Jove R., Pardoll D., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11:1314-1321.
43. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
44. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56:4625-4629.
45. Leek R.D., Landers R.J., Harris A.L., Lewis C.E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 1999, 79:991-995.
46. Levy D.E., Inghirami G. STAT3: A multifaceted oncogene. Proc. Natl. Acad. Sci. USA 2006, 103:10151-10152.
47. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
48. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193:727-740.
49. Luo Y., Zhou H., Krueger J., Kaplan C., Lee S.H., Dolman C., Markowitz D., Wu W., Liu C., Reisfeld R.A., Xiang R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 2006, 116:2132-2141.
50. Mantovani A. Cancer: Inflaming metastasis. Nature 2009, 457:36-37.
51. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
52. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
53. Mantovani A., Sica A., Allavena P., Garlanda C., Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 2009, 70:325-330.
54. Martino A., Badell E., Abadie V., Balloy V., Chignard M., Mistou M.Y., Combadiere B., Combadiere C., Winter N. Mycobacterium bovis bacillus Calmette-Guerin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production. J. Immunol. 2010, 184:2038-2047.
55. McCarthy E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 2006, 26:154-158.
56. Medzhitov R., Horng T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 2009, 9:692-703.
57. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
58. Morris L., Graham C.F., Gordon S. Macrophages in haemopoietic and other tissues of the developing mouse detected by the monoclonal antibody F4/80. Development 1991, 112:517-526.
59. Murray P.J. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 2006, 6:379-386.
60. Murray P.J. The JAK-STAT signaling pathway: Input and output integration. J. Immunol. 2007, 178:2623-2629.
61. Mytar B., Woloszyn M., Szatanek R., Baj-Krzyworzeka M., Siedlar M., Ruggiero I., Wieckiewicz J., Zembala M. Tumor cell-induced deactivation of human monocytes. J. Leukoc. Biol. 2003, 74:1094-1101.
62. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D.L., Schneck J., Gabrilovich D.I. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 2007, 13:828-835.
63. Negus R.P., Stamp G.W., Hadley J., Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 1997, 150:1723-1734.
64. O'Shea J.J., Murray P.J. Cytokine signaling modules in inflammatory responses. Immunity 2008, 28:477-487.
65. Ohno S., Inagawa H., Dhar D.K., Fujii T., Ueda S., Tachibana M., Suzuki N., Inoue M., Soma G., Nagasue N. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res. 2003, 23:5015-5022.
66. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
67. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353:2654-2666.
68. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., Osterreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
69. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009, 206:1717-1725.
70. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 2010, 22(2):238-244.
71. Pesce J.T., Ramalingam T.R., Mentink-Kane M.M., Wilson M.S., El Kasmi K.C., Smith A.M., Thompson R.W., Cheever A.W., Murray P.J., Wynn T.A. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 2009, 5:e1000371.
72. Pierce B.L., Ballard-Barbash R., Bernstein L., Baumgartner R.N., Neuhouser M.L., Wener M.H., Baumgartner K.B., Gilliland F.D., Sorensen B.E., McTiernan A., Ulrich C.M. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 2009, 27:3437-3444.
73. Pils M.C., Pisano F., Fasnacht N., Heinrich J.M., Groebe L., Schippers A., Rozell B., Jack R.S., Muller W. Monocytes/macrophages and/or neutrophils are the target of IL-10 in the LPS endotoxemia model. Eur. J. Immunol. 2010, 40:443-448.
74. Piras F., Colombari R., Minerba L., Murtas D., Floris C., Maxia C., Corbu A., Perra M.T., Sirigu P. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005, 104:1246-1254.
75. Pollard J.W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 2008, 84:623-630.
76. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat. Rev. Cancer 2009, 9:57-63.
77. Rolny C., Capparuccia L., Casazza A., Mazzone M., Vallario A., Cignetti A., Medico E., Carmeliet P., Comoglio P.M., Tamagnone L. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J. Exp. Med. 2008, 205:1155-1171.
78. Saccani A., Schioppa T., Porta C., Biswas S.K., Nebuloni M., Vago L., Bottazzi B., Colombo M.P., Mantovani A., Sica A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66:11432-11440.
79. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010, 10:170-181.
80. Serafini P., Borrello I., Bronte V. Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16:53-65.
81. Serbina N.V., Salazar-Mather T.P., Biron C.A., Kuziel W.A., Pamer E.G. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003, 19:59-70.
82. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J., Mantovani A. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 2000, 164:762-767.
83. Sica A., Allavena P., Mantovani A. Cancer related inflammation: The macrophage connection. Cancer Lett. 2008, 267:204-215.
84. Sinha P., Clements V.K., Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005, 65:11743-11751.
85. Skold M., Behar S.M. Tuberculosis triggers a tissue-dependent program of differentiation and acquisition of effector functions by circulating monocytes. J. Immunol. 2008, 181:6349-6360.
86. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009, 86:1065-1073.
87. Swirski F.K., Nahrendorf M., Etzrodt M., Wildgruber M., Cortez-Retamozo V., Panizzi P., Figueiredo J.L., Kohler R.H., Chudnovskiy A., Waterman P., Aikawa E., Mempel T.R., et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009, 325:612-616.
88. Torroella-Kouri M., Ma X., Perry G., Ivanova M., Cejas P.J., Owen J.L., Iragavarapu-Charyulu V., Lopez D.M. Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice. Cancer Res. 2005, 65:10578-10584.
89. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10:48-54.
90. Wyckoff J.B., Wang Y., Lin E.Y., Li J.F., Goswami S., Stanley E.R., Segall J.E., Pollard J.W., Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67:2649-2656.
91. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
92. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
93. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.